About The Study: In this systematic review and meta-analysis of 18 trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with type 2 diabetes or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although gastrointestinal adverse effects warrant attention in long-term management.
Corresponding Author: To contact the corresponding author, Jingchuan Guo, MD, PhD, email guoj1@ufl.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2025.3243)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.3243?guestAccessKey=5984867c-844f-4c44-83ca-3837692ff37e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525
JAMA Pediatrics